Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant ...

GAITHERSBURG, Md., Oct. 3, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax ...

On August 30, 2024, the Food and Drug Administration amended the emergency use authorization (EUA) of Novavax COVID-19 Vaccine, Adjuvanted to include the updated 2024-2025 formula. The Novavax ...

Novavax received emergency use authorization for an updated vaccine. The biotech is benefiting from a partnership with Sanofi. However, its prospects remain unpredictable. Though we are no longer in a ...

Novavax is available through an Emergency Use Authorization (EUA). An EUA helps make vaccines, drugs, or tests available quickly in the event of an emergency. The Food and Drug Administration (FDA) ...

The U.S. Food and Drug Administration (FDA) has just extended the emergency use authorization (EUA) for Novavax’s adjuvanted (NVX-CoV2373) Covid-19 vaccine to now include a first booster dose for ...

The Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and ...

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M ™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing ...

Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring.